{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T18:56:48Z","timestamp":1774292208517,"version":"3.50.1"},"reference-count":54,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["AIAAMC"],"published-print":{"date-parts":[[2020,6,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Non-steroidal anti-inflammatory drugs, e.g., celecoxib, are commonly\nused for inflammatory conditions, but can be associated with adverse effects. Combined\nglucosamine hydrochloride plus chondroitin sulfate (GH+CS) are commonly used\nfor joint pain and have no known adverse effects. Evidence from in vitro, animal and human\nstudies suggest that GH+CS have anti-inflammatory activity, among other mechanisms\nof action.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>We evaluated the effects of GH+CS versus celecoxib on a panel of 20 serum\nproteins involved in inflammation and other metabolic pathways.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Samples were from a randomized, parallel, double-blind trial of pharmaceutical\ngrade 1500 mg GH + 1200 mg CS (n=96) versus 200 mg celecoxib daily (n=93) for 6-\nmonths in knee osteoarthritis (OA) patients. Linear mixed models adjusted for age, sex,\nbody mass index, baseline serum protein values, and rescue medicine use assessed the intervention\neffects of each treatment arm adjusting for multiple testing.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>All serum proteins except WNT16 were lower after treatment with GH+CS, while\nabout half increased after celecoxib. Serum IL-6 was significantly reduced (by 9%,\nP=0.001) after GH+CS, and satisfied the FDR &lt;0.05 threshold. CCL20, CSF3, and WNT16\nincreased after celecoxib (by 7%, 9% and 9%, respectively, P&lt;0.05), but these serum proteins\nwere no longer statistically significant after controlling for multiple testing.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The results of this study using samples from a previously conducted trial in\nOA patients, demonstrate that GH+CS reduces circulating IL-6, an inflammatory cytokine,\nbut is otherwise comparable to celecoxib with regard to effects on other circulating protein\nbiomarkers.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871523018666190115094512","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T11:22:41Z","timestamp":1547637761000},"page":"190-201","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Differences in Serum Biomarkers Between Combined Glucosamine and Chondroitin Versus Celecoxib in a Randomized, Double-blind Trial in Osteoarthritis Patients"],"prefix":"10.2174","volume":"19","author":[{"given":"Sandi L.","family":"Navarro","sequence":"first","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Herrero","sequence":"additional","affiliation":[{"name":"Bioiberica S.A.U., Plaza Francesc Macia 7, 08029 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Martinez","sequence":"additional","affiliation":[{"name":"Bioiberica S.A.U., Plaza Francesc Macia 7, 08029 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Ladd","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Lo","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Shelley","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy W.","family":"Randolph","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna W.","family":"Lampe","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Lampe","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"10593","DOI":"10.1038\/srep10593","volume":"5","author":"Zeng C.","year":"2015","unstructured":"Zeng C.; Wei J.; Li H.; Yang T.; Gao S.G.; Li Y.S.; Xiong Y.L.; Xiao W.F.; Luo W.; Yang T.B.; Lei G.H.; Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis. Sci Rep 2015,5,10593","journal-title":"Sci Rep"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bpg.2009.11.005","volume":"24","author":"Sostres C.","year":"2010","unstructured":"Sostres C.; Gargallo C.J.; Arroyo M.T.; Lanas A.; Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010,24(2),121-132","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"Bhala N.","year":"2013","unstructured":"Bhala N.; Emberson J.; Merhi A.; Abramson S.; Arber N.; Baron J.A.; Bombardier C.; Cannon C.; Farkouh M.E.; FitzGerald G.A.; Goss P.; Halls H.; Hawk E.; Hawkey C.; Hennekens C.; Hochberg M.; Holland L.E.; Kearney P.M.; Laine L.; Lanas A.; Lance P.; Laupacis A.; Oates J.; Patrono C.; Schnitzer T.J.; Solomon S.; Tugwell P.; Wilson K.; Wittes J.; Baigent C.; Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet Coxib and traditional NSAID Trialists\u2019 (CNT) Collaboration2013,382(9894),769-779","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.joca.2007.12.013","volume":"16","author":"Zhang W.","year":"2008","unstructured":"Zhang W.; Moskowitz R.W.; Nuki G.; Abramson S.; Altman R.D.; Arden N.; Bierma-Zeinstra S.; Brandt K.D.; Croft P.; Doherty M.; Dougados M.; Hochberg M.; Hunter D.J.; Kwoh K.; Lohmander L.S.; Tugwell P.; OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008,16(2),137-162","journal-title":"Osteoarthritis Cartilage"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa052771","volume":"354","author":"Clegg D.O.","year":"2006","unstructured":"Clegg D.O.; Reda D.J.; Harris C.L.; Klein M.A.; O\u2019Dell J.R.; Hooper M.M.; Bradley J.D.; Bingham C.O.; Weisman M.H.; Jackson C.G.; Lane N.E.; Cush J.J.; Moreland L.W.; Schumacher H.R.; Oddis C.V.; Wolfe F.; Molitor J.A.; Yocum D.E.; Schnitzer T.J.; Furst D.E.; Sawitzke A.D.; Shi H.; Brandt K.D.; Moskowitz R.W.; Williams H.J.; Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006,354(8),795-808","journal-title":"N Engl J Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/annrheumdis-2014-206792","volume":"75","author":"Hochberg M.C.","year":"2016","unstructured":"Hochberg M.C.; Martel-Pelletier J.; Monfort J.; M\u00f6ller I.; Castillo J.R.; Arden N.; Berenbaum F.; Blanco F.J.; Conaghan P.G.; Dom\u00e9nech G.; Henrotin Y.; Pap T.; Richette P.; Sawitzke A.; du Souich P.; Pelletier J.P.; Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis MOVES Investigation Group2016,75(1),37-44","journal-title":"Ann Rheum Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1136\/ard.2009.120469","volume":"69","author":"Sawitzke A.D.","year":"2010","unstructured":"Sawitzke A.D.; Shi H.; Finco M.F.; Dunlop D.D.; Harris C.L.; Singer N.G.; Bradley J.D.; Silver D.; Jackson C.G.; Lane N.E.; Oddis C.V.; Wolfe F.; Lisse J.; Furst D.E.; Bingham C.O.; Reda D.J.; Moskowitz R.W.; Williams H.J.; Clegg D.O.; Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010,69(8),1459-1464","journal-title":"Ann Rheum Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S1063-4584(03)00028-1","volume":"11","author":"Largo R.","year":"2003","unstructured":"Largo R.; Alvarez-Soria M.A.; D\u00edez-Ortego I.; Calvo E.; S\u00e1nchez-Pernaute O.; Egido J.; Herrero-Beaumont G.; Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003,11(4),290-298","journal-title":"Osteoarthritis Cartilage"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.canlet.2008.01.022","volume":"264","author":"Xu C.X.","year":"2008","unstructured":"Xu C.X.; Jin H.; Chung Y.S.; Shin J.Y.; Woo M.A.; Lee K.H.; Palmos G.N.; Choi B.D.; Cho M.H.; Chondroitin sulfate extracted from the Styela clava tunic suppresses TNF-alpha-induced expression of inflammatory factors, VCAM-1 and iNOS by blocking Akt\/NF-kappaB signal in JB6 cells. Cancer Lett 2008,264(1),93-100","journal-title":"Cancer Lett"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"H268","DOI":"10.1152\/ajpheart.00142.2009","volume":"297","author":"Largo R.","year":"2009","unstructured":"Largo R.; Mart\u00ednez-Calatrava M.J.; S\u00e1nchez-Pernaute O.; Marcos M.E.; Moreno-Rubio J.; Aparicio C.; Egido J.; Herrero-Beaumont G.; Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis. Am J Physiol Heart Circ Physiol 2009,297(1),H268-H276","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s00011-007-7020-7","volume":"56","author":"Hua J.","year":"2007","unstructured":"Hua J.; Sakamoto K.; Kikukawa T.; Abe C.; Kurosawa H.; Nagaoka I.; Evaluation of the suppressive actions of glucosamine on the interleukin-1beta-mediated activation of synoviocytes. Inflamm Res 2007,56(10),432-438","journal-title":"Inflamm Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/153537020523000405","volume":"230","author":"Chou M.M.","year":"2005","unstructured":"Chou M.M.; Vergnolle N.; McDougall J.J.; Wallace J.L.; Marty S.; Teskey V.; Buret A.G.; Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med (Maywood) 2005,230(4),255-262","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1254\/jjp.85.155","volume":"85","author":"Hori Y.","year":"2001","unstructured":"Hori Y.; Hoshino J.; Yamazaki C.; Sekiguchi T.; Miyauchi S.; Horie K.; Effects of chondroitin sulfate on colitis induced by dextran sulfate sodium in rats. Jpn J Pharmacol 2001,85(2),155-160","journal-title":"Jpn J Pharmacol"},{"key":"ref=14","first-page":"317","volume":"22","author":"Yomogida S.","year":"2008","unstructured":"Yomogida S.; Kojima Y.; Tsutsumi-Ishii Y.; Hua J.; Sakamoto K.; Nagaoka I.; Glucosamine, a naturally occurring amino monosaccharide, suppresses dextran sulfate sodium-induced colitis in rats. Int J Mol Med 2008,22(3),317-323","journal-title":"Int J Mol Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/aje\/kws186","volume":"176","author":"Kantor E.D.","year":"2012","unstructured":"Kantor E.D.; Lampe J.W.; Vaughan T.L.; Peters U.; Rehm C.D.; White E.; Association between use of specialty dietary supplements and C-reactive protein concentrations. Am J Epidemiol 2012,176(11),1002-1013","journal-title":"Am J Epidemiol"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117534","volume":"10","author":"Navarro S.L.","year":"2015","unstructured":"Navarro S.L.; White E.; Kantor E.D.; Zhang Y.; Rho J.; Song X.; Milne G.L.; Lampe P.D.; Lampe J.W.; Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One 2015,10(2)","journal-title":"PLoS One"},{"key":"ref=17","first-page":"1833","volume":"15","author":"Bellamy N.","year":"1988","unstructured":"Bellamy N.; Buchanan W.W.; Goldsmith C.H.; Campbell J.; Stitt L.W.; Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988,15(12),1833-1840","journal-title":"J Rheumatol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/ard.16.4.494","volume":"16","author":"Kellgren J.H.","year":"1957","unstructured":"Kellgren J.H.; Lawrence J.S.; Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957,16(4),494-502","journal-title":"Ann Rheum Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.molonc.2007.08.004","volume":"1","author":"Loch C.M.","year":"2007","unstructured":"Loch C.M.; Ramirez A.B.; Liu Y.; Sather C.L.; Delrow J.J.; Scholler N.; Garvik B.M.; Urban N.D.; McIntosh M.W.; Lampe P.D.; Use of high density antibody arrays to validate and discover cancer serum biomarkers. Mol Oncol 2007,1(3),313-320","journal-title":"Mol Oncol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1021\/pr4001674","volume":"12","author":"Rho J.H.","year":"2013","unstructured":"Rho J.H.; Lampe P.D.; High-throughput screening for native autoantigen-autoantibody complexes using antibody microarrays. J Proteome Res 2013,12(5),2311-2320","journal-title":"J Proteome Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1074\/mcp.M900496-MCP200","volume":"9","author":"Ramirez A.B.","year":"2010","unstructured":"Ramirez A.B.; Loch C.M.; Zhang Y.; Liu Y.; Wang X.; Wayner E.A.; Sargent J.E.; Sibani S.; Hainsworth E.; Mendoza E.A.; Eugene R.; Labaer J.; Urban N.D.; McIntosh M.W.; Lampe P.D.; Use of a single-chain antibody library for ovarian cancer biomarker discovery. Mol Cell Proteomics 2010,9(7),1449-1460","journal-title":"Mol Cell Proteomics"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1158\/1078-0432.CCR-13-3474","volume":"21","author":"Mirus J.E.","year":"2015","unstructured":"Mirus J.E.; Zhang Y.; Li C.I.; Lokshin A.E.; Prentice R.L.; Hingorani S.R.; Lampe P.D.; Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer. Clin Cancer Res 2015,21(7),1764-1771","journal-title":"Clin Cancer Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jprot.2013.10.030","volume":"96","author":"Rho J.H.","year":"2014","unstructured":"Rho J.H.; Mead J.R.; Wright W.S.; Brenner D.E.; Stave J.W.; Gildersleeve J.C.; Lampe P.D.; Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays. J Proteomics 2014,96,291-299","journal-title":"J Proteomics"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10549-012-2204-4","volume":"135","author":"Li C.I.","year":"2012","unstructured":"Li C.I.; Mirus J.E.; Zhang Y.; Ramirez A.B.; Ladd J.J.; Prentice R.L.; McIntosh M.W.; Hanash S.M.; Lampe P.D.; Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women\u2019s Health Initiative observational study. Breast Cancer Res Treat 2012,135(2),611-618","journal-title":"Breast Cancer Res Treat"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1158\/1055-9965.EPI-06-0223","volume":"15","author":"McTiernan A.","year":"2006","unstructured":"McTiernan A.; Yasui Y.; Sorensen B.; Irwin M.L.; Morgan A.; Rudolph R.E.; Surawicz C.; Lampe J.W.; Ayub K.; Potter J.D.; Lampe P.D.; Effect of a 12-month exercise intervention on patterns of cellular proliferation in colonic crypts: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2006,15(9),1588-1597","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/CBM-2011-0215","volume":"8","author":"Ramirez A.B.","year":"2010-2011","unstructured":"Ramirez A.B.; Lampe P.D.; Discovery and validation of ovarian cancer biomarkers utilizing high density antibody microarrays. Cancer Biomark 2010-2011,8(4-5),293-307","journal-title":"Cancer Biomark"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/0-387-29362-0_23","author":"Smyth G.K.","year":"2005","unstructured":"Smyth G.K.;  Bioinformatics and Computational Biology Solutions Using R and Bioconductor In: 2005,397-420","journal-title":"Bioinformatics and Computational Biology Solutions Using R and Bioconductor In:"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1046-2023(03)00155-5","volume":"31","author":"Smyth G.K.","year":"2003","unstructured":"Smyth G.K.; Speed T.; Normalization of cDNA microarray data. Methods 2003,31(4),265-273","journal-title":"Methods"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/0049-0172(89)90010-3","volume":"18","author":"Bellamy N.","year":"1989","unstructured":"Bellamy N.; Pain assessment in osteoarthritis: experience with the WOMAC osteoarthritis index. Semin Arthritis Rheum 1989,18(4)(Suppl. 2),14-17","journal-title":"Semin Arthritis Rheum"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Benjamini Y.","year":"1995","unstructured":"Benjamini Y.; Hochberg Y.; Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Roy Stat Soc B Met 1995,57(1),289-300","journal-title":"J Roy Stat Soc B Met"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1158\/1055-9965.EPI-15-0956","volume":"25","author":"Navarro S.L.","year":"2016","unstructured":"Navarro S.L.; Kantor E.D.; Song X.; Milne G.L.; Lampe J.W.; Kratz M.; White E.; Factors associated with multiple biomarkers of systemic inflammation. Cancer Epidemiol Biomarkers Prev 2016,25(3),521-531","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrrheum.2010.196","volume":"7","author":"Kapoor M.","year":"2011","unstructured":"Kapoor M.; Martel-Pelletier J.; Lajeunesse D.; Pelletier J.P.; Fahmi H.; Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011,7(1),33-42","journal-title":"Nat Rev Rheumatol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/13684730050515796","volume":"6","author":"Kaneko S.","year":"2000","unstructured":"Kaneko S.; Satoh T.; Chiba J.; Ju C.; Inoue K.; Kagawa J.; Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther 2000,6(2),71-79","journal-title":"Cytokines Cell Mol Ther"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nrm2125","volume":"8","author":"Page-McCaw A.","year":"2007","unstructured":"Page-McCaw A.; Ewald A.J.; Werb Z.; Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007,8(3),221-233","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1074\/jbc.M706387200","volume":"283","author":"Por\u00e9e B.","year":"2008","unstructured":"Por\u00e9e B.; Kypriotou M.; Chadjichristos C.; Beauchef G.; Renard E.; Legendre F.; Melin M.; Gueret S.; Hartmann D.J.; Mall\u00e9in-Gerin F.; Pujol J.P.; Boumediene K.; Gal\u00e9ra P.; Interleukin-6 (IL-6) and\/or soluble IL-6 receptor down-regulation of human type II collagen gene expression in articular chondrocytes requires a decrease of Sp1.Sp3 ratio and of the binding activity of both factors to the COL2A1 promoter. J Biol Chem 2008,283(8),4850-4865","journal-title":"J Biol Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.joca.2008.06.008","volume":"16","author":"Iovu M.","year":"2008","unstructured":"Iovu M.; Dumais G.; du Souich P.; Anti-inflammatory activity of chondroitin sulfate. Osteoarthr Cartilage 2008,16(Suppl. 3),S14-S18","journal-title":"Osteoarthr Cartilage"},{"key":"ref=37","first-page":"1329","volume":"33","author":"Chan P.S.","year":"2006","unstructured":"Chan P.S.; Caron J.P.; Orth M.W.; Short-term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate. J Rheumatol 2006,33(7),1329-1340","journal-title":"J Rheumatol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/jgh.12485","volume":"29","author":"Bak Y.K.","year":"2014","unstructured":"Bak Y.K.; Lampe J.W.; Sung M.K.; Dietary supplementation of glucosamine sulfate attenuates intestinal inflammation in a mouse model of experimental colitis. J Gastroenterol Hepatol 2014,29,957-963","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1007\/s10753-012-9459-0","volume":"35","author":"Azuma K.","year":"2012","unstructured":"Azuma K.; Osaki T.; Wakuda T.; Tsuka T.; Imagawa T.; Okamoto Y.; Minami S.; Suppressive effects of N-acetyl-D-glucosamine on rheumatoid arthritis mouse models. Inflammation 2012,35(4),1462-1465","journal-title":"Inflammation"},{"key":"ref=40","first-page":"205","volume":"22","author":"Yomogida S.","year":"2008","unstructured":"Yomogida S.; Hua J.; Sakamoto K.; Nagaoka I.; Glucosamine suppresses interleukin-8 production and ICAM-1 expression by TNF-alpha-stimulated human colonic epithelial HT-29 cells. Int J Mol Med 2008,22(2),205-211","journal-title":"Int J Mol Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.niox.2013.02.082","volume":"31","author":"Hwang S.Y.","year":"2013","unstructured":"Hwang S.Y.; Hwang J.S.; Kim S.Y.; Han I.O.; Glucosamine inhibits lipopolysaccharide-stimulated inducible nitric oxide synthase induction by inhibiting expression of NF-kappaB\/Rel proteins at the mRNA and protein levels. Nitric Oxide 2013,31,1-8","journal-title":"Nitric Oxide"},{"key":"ref=42","first-page":"175","volume":"21","author":"Nakamura H.","year":"2002","unstructured":"Nakamura H.; Nishioka K.; Effects of glucosamine\/chondroitin supplement on osteoarthritis: involvement of PGE2 and YKL-40. J Rheumatism Joint Surg 2002,21,175-184","journal-title":"J Rheumatism Joint Surg"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00296-006-0197-1","volume":"27","author":"Nakamura H.","year":"2007","unstructured":"Nakamura H.; Masuko K.; Yudoh K.; Kato T.; Kamada T.; Kawahara T.; Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int 2007,27(3),213-218","journal-title":"Rheumatol Int"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1089\/acm.2013.0323","volume":"20","author":"Kantor E.D.","year":"2014","unstructured":"Kantor E.D.; Lampe J.W.; Navarro S.L.; Song X.; Milne G.L.; White E.; Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation. J Altern Complement Med 2014,20(6),479-485","journal-title":"J Altern Complement Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1158\/1055-9965.EPI-13-0470","volume":"22","author":"Kantor E.D.","year":"2013","unstructured":"Kantor E.D.; Ulrich C.M.; Owen R.W.; Schmezer P.; Neuhouser M.L.; Lampe J.W.; Peters U.; Shen D.D.; Vaughan T.L.; White E.; Specialty supplement use and biologic measures of oxidative stress and DNA damage. Cancer Epidemiol Biomarkers Prev 2013,22(12),2312-2322","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=46","first-page":"17","volume":"40","author":"Madjid M.","year":"2013","unstructured":"Madjid M.; Fatemi O.; Components of the complete blood count as risk predictors for coronary heart disease: in-depth review and update. Tex Heart Inst J 2013,40(1),17-29","journal-title":"Tex Heart Inst J"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1749-6632.2011.06096.x","volume":"1229","author":"Harvey A.E.","year":"2011","unstructured":"Harvey A.E.; Lashinger L.M.; Hursting S.D.; The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci 2011,1229,45-52","journal-title":"Ann N Y Acad Sci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.coph.2009.06.018","volume":"9","author":"Aggarwal B.B.","year":"2009","unstructured":"Aggarwal B.B.; Inflammation, a silent killer in cancer is not so silent! Curr Opin Pharmacol 2009,9(4),347-350","journal-title":"Curr Opin Pharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ijbiomac.2016.04.091","volume":"89","author":"Shang Q.","year":"2016","unstructured":"Shang Q.; Shi J.; Song G.; Zhang M.; Cai C.; Hao J.; Li G.; Yu G.; Structural modulation of gut microbiota by chondroitin sulfate and its oligosaccharide. Int J Biol Macromol 2016,89,489-498","journal-title":"Int J Biol Macromol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijbiomac.2016.01.055","volume":"86","author":"Shang Q.","year":"2016","unstructured":"Shang Q.; Yin Y.; Zhu L.; Li G.; Yu G.; Wang X.; Degradation of chondroitin sulfate by the gut microbiota of Chinese individuals. Int J Biol Macromol 2016,86,112-118","journal-title":"Int J Biol Macromol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","volume":"44","author":"Kim S.","year":"2016","unstructured":"Kim S.; Thiessen P.A.; Bolton E.E.; Chen J.; Fu G.; Gindulyte A.; Han L.; He J.; He S.; Shoemaker B.A.; Wang J.; Yu B.; Zhang J.; Bryant S.H.; PubChem substance and compound databases. Nucleic Acids Res 2016,44(D1),D1202-D1213","journal-title":"Nucleic Acids Res"},{"key":"ref=52","unstructured":"National Center for Biotechnology InformationPub-\n\tChem Compound Database; Glucosamine Hydrochloride;\n\tCID=91431;    https:\/\/pubchem.ncbi.nlm.nih.gov\/ compound\/45933886 (accessed Dec 17, 2018)."},{"key":"ref=53","unstructured":"National Center for Biotechnology Information Pub-\n\tChem Compound Database; Chondroitin Sulfate;\nCID=24766;     https:\/\/pubchem.ncbi.nlm.nih.gov\/com pound\/24766 (accessed Dec 17, 2018)."},{"key":"ref=54","unstructured":"National Center for Biotechnology InformationPub-\n\tChem Compound Database; Celecoxib; CID=2662,  https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/2662 (accessed Dec 17, 2018)."}],"container-title":["Anti-Inflammatory &amp; Anti-Allergy Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/168994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T06:21:09Z","timestamp":1596349269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/168994\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871523018666190115094512","relation":{},"ISSN":["1871-5230"],"issn-type":[{"value":"1871-5230","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-10-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}